

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: PAPIEROK, Gérard; VICENS, Serge; LEMESRE, Jean-Loup

SERIAL NO.: (International Serial No. PCT/FR03/002358)

FILED: Herewith (International Filing Date: 25 July 2003)

TITLE: SPECIFIC ISOTYPE ANTIBODIES OF SECRETION-EXCRETION ANTI-ANTIGENS OF *LEISHMANIA SP* OF PROMASTIGOTE OR AMASTIGOTE FORMS, etc...

Preliminary Amendment: CLAIM AMENDMENTS

1. (Original) Immunoglobulins characterized in that they are immunoglobulins of the classes IgG₂ and corresponding sub-classes, specific to the excretion-secretion antigens of promastigotes or amastigotes of *Leishmania sp*, capable of lysing the amastigotes and promastigotes of *Leishmania sp* in vitro and neutralizing their proliferation.

2. (Original) Immunoglobulins according to claim 1, characterized in that they are specific to the major immunogen, excreted-secreted by promastigotes or amastigotes of *Leishmania sp*, belonging to the family of the *Protein Surface Antigens* and corresponding to a range of molecular mass from 52 to 58 Kda.

3. (Original) Immunoglobulins according to claim 2, characterized in that they are specific to the carboxyterminal part of the major excreted-secreted immunogen.

4. (Currently amended) Immunoglobulins according to ~~any one of the claims 1 to 3~~ Claim 1, characterized in that they are isotypes IgG₂ in dogs and specific isotypes in other mammals, isotypes linked to cell-mediated immunity depending on T lymphocytes of the Th1 type.

5. (Currently amended) Use of immunoglobulins according to Claim 1 ~~any one of the claims 1 to 4~~ as markers of a cell-mediated immunity allowing notably the detection of a cell-mediated immunity depending on T lymphocytes and preferably T lymphocytes of the Th1 type in mammals.

6. (Currently amended) Use of immunoglobulins according to ~~any one of the claims 1 to 4~~ Claim 1 as markers of the resistance to leishmaniasis and to infections by pathogenic intracellular micro-organisms in mammals.

7. (Currently amended) Use of immunoglobulins according to ~~any one of the claims 1 to 4~~ Claim 1 as markers of immunoprophylactic and immunotherapeutic vaccination in mammals for leishmaniasis and infections by pathogenic intracellular micro-organisms.

8. (Currently amended) Immunoglobulins according to ~~any one of the claims 1 to 4~~ Claim 1, as effectors of immunotherapy in the context of leishmaniasis and infections by pathogenic intracellular micro-organisms in mammals.

9. (Currently amended) Use of immunoglobulins according to ~~claims 1 to 4~~ Claim 1, for an in vitro diagnostic product detecting one or more epitopes carried by the terminal ends NH₂ and COOH of the Protein Surface Antigens excreted-secreted by *Leishmania sp.*